Alyeska Investment Group L.P. Sells 936,707 Shares of MDxHealth SA $MDXH

Key Points

• Alyeska Investment Group L.P. has reduced its stake in MDxHealth SA by 93.0%, now holding only 70,293 shares valued at $100,000 after selling 936,707 shares in Q1.
• Despite the sell-off by Alyeska, several other institutional investors, including Northern Trust Corp and Perkins Capital Management Inc., have made new purchases or increased their positions in MDxHealth during Q4 and Q1.
• MDxHealth recently reported a quarterly loss of ($0.15) EPS, missing estimates, while analysts currently rate the stock with a consensus "Buy" and an average target price of $7.00.

Alyeska Investment Group L.P. cut its position in shares of MDxHealth SA (NASDAQ:MDXH - Free Report) by 93.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 70,293 shares of the company's stock after selling 936,707 shares during the quarter. Alyeska Investment Group L.P. owned approximately 0.15% of MDxHealth worth $100,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Castleview Partners LLC purchased a new position in MDxHealth in the first quarter valued at about $48,000. Delta Investment Management LLC purchased a new stake in shares of MDxHealth during the 4th quarter valued at approximately $81,000. Northern Trust Corp purchased a new stake in shares of MDxHealth during the 4th quarter valued at approximately $1,033,000. Perkins Capital Management Inc. lifted its stake in shares of MDxHealth by 20.1% during the 1st quarter. Perkins Capital Management Inc. now owns 1,181,475 shares of the company's stock valued at $1,678,000 after buying an additional 198,000 shares in the last quarter. Finally, AWM Investment Company Inc. increased its holdings in MDxHealth by 11.1% during the 4th quarter. AWM Investment Company Inc. now owns 4,721,290 shares of the company's stock worth $11,189,000 after acquiring an additional 471,290 shares during the period.

MDxHealth Stock Performance

Shares of MDXH stock traded down $0.14 during trading hours on Friday, reaching $3.69. The company had a trading volume of 204,689 shares, compared to its average volume of 165,996. The business has a fifty day moving average price of $2.86 and a 200-day moving average price of $2.17. MDxHealth SA has a one year low of $1.35 and a one year high of $3.91. The firm has a market cap of $174.50 million, a PE ratio of -4.19 and a beta of 1.49. The company has a debt-to-equity ratio of 13.81, a quick ratio of 1.22 and a current ratio of 1.31.

MDxHealth (NASDAQ:MDXH - Get Free Report) last announced its earnings results on Tuesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.02). The business had revenue of $26.60 million for the quarter, compared to the consensus estimate of $26.60 million. MDxHealth had a negative net margin of 34.98% and a negative return on equity of 374.98%. MDxHealth has set its Q2 2025 guidance at -0.150--0.150 EPS. Sell-side analysts predict that MDxHealth SA will post -1.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on MDXH shares. Wall Street Zen raised shares of MDxHealth to a "hold" rating in a report on Saturday, August 30th. Craig Hallum started coverage on shares of MDxHealth in a report on Thursday, July 17th. They set a "buy" rating and a $8.00 target price on the stock. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, MDxHealth currently has a consensus rating of "Buy" and an average target price of $7.00.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.